Table 2. Summary of results for the three-stage association study.
SNP | PhysicalPositiona | AnnotatedGene | Allele(A/B)b | Stage | Case | MAF | Control | MAF | P-valuec | OR (95% CI)c | ||||
AA | AB | BB | AA | AB | BB | |||||||||
rs9276370 | Chr6: 32815273 | HLA-DQA2 | G/T | GWAS | 0.003 | 0.137 | 0.860 | 0.072 | 0.020 | 0.260 | 0.720 | 0.150 | 3.57×10−5 | 2.25 (1.53–3.31) |
1st replication | 0.006 | 0.1271 | 0.867 | 0.070 | 0.012 | 0.194 | 0.793 | 0.110 | 2.90×10−3 | 1.65 (1.19–2.30) | ||||
2nd replication | 0.006 | 0.157 | 0.857 | 0.085 | 0.015 | 0.260 | 0.725 | 0.145 | 2.09×10−5 | 1.87 (1.40–2.50) | ||||
Combined | 0.006 | 0.141 | 0.853 | 0.076 | 0.015 | 0.240 | 0.745 | 0.135 | 1.90×10−12 | 1.95 (1.62–2.34) | ||||
rs7756516 | Chr6: 32831895 | HLA-DQB2 | C/T | GWAS | 0.012 | 0.128 | 0.860 | 0.076 | 0.020 | 0.280 | 0.701 | 0.160 | 1.97×10−5 | 2.24 (1.55–3.23) |
1st replication | 0.008 | 0.124 | 0.867 | 0.071 | 0.012 | 0.204 | 0.784 | 0.114 | 1.35×10−3 | 1.71 (1.23–2.37) | ||||
2nd replication | 0.007 | 0.176 | 0.818 | 0.094 | 0.017 | 0.260 | 0.723 | 0.147 | 3.26×10−4 | 1.69 (1.27–2.25) | ||||
Combined | 0.009 | 0.146 | 0.846 | 0.081 | 0.016 | 0.248 | 0.736 | 0.140 | 1.48×10−11 | 1.87 (1.56–2.25) | ||||
rs7453920* | Chr6: 32837990 | HLA-DQB2 | A/G | GWAS | 0.003 | 0.084 | 0.913 | 0.045 | 0.016 | 0.207 | 0.776 | 0.120 | 9.24×10−6 | 2.77 (1.77–4.35) |
1st replication | 0.003 | 0.093 | 0.904 | 0.050 | 0.015 | 0.181 | 0.804 | 0.105 | 1.02×10−5 | 2.22 (1.56–3.16) | ||||
2nd replication | 0.002 | 0.109 | 0.890 | 0.056 | 0.010 | 0.192 | 0.798 | 0.106 | 2.15×10−5 | 2.08 (1.48–2.91) | ||||
Combined | 0.003 | 0.098 | 0.900 | 0.051 | 0.013 | 0.193 | 0.794 | 0.110 | 6.66×10−15 | 2.31 (1.87–2.85) | ||||
rs9277535* | Chr6: 33162839 | HLA-DPB1 | A/G | GWAS | 0.062 | 0.343 | 0.595 | 0.234 | 0.106 | 0.503 | 0.391 | 0.358 | 1.80×10−6 | 1.87 (1.45–2.42) |
1st replication | 0.071 | 0.357 | 0.572 | 0.249 | 0.142 | 0.428 | 0.431 | 0.355 | 3.64×10−6 | 1.61 (1.32–1.98) | ||||
2nd replication | 0.076 | 0.372 | 0.553 | 0.262 | 0.125 | 0.431 | 0.443 | 0.341 | 8.72×10−5 | 1.47 (1.21–1.78) | ||||
Combined | 0.071 | 0.360 | 0.569 | 0.251 | 0.125 | 0.451 | 0.424 | 0.350 | 4.87×10−14 | 1.59 (1.41–1.79) | ||||
rs9366816* | Chr6: 33212153 | HLA-DPA3 | C/T | GWAS | 0.393 | 0.442 | 0.165 | 0.386 | 0.188 | 0.566 | 0.247 | 0.470 | 1.07×10−6 | 1.80 (1.42–2.27) |
1st replication | 0.353 | 0.456 | 0.191 | 0.419 | 0.247 | 0.531 | 0.222 | 0.488 | 5.45×10−3 | 1.31 (1.08–1.58) | ||||
2nd replication | 0.353 | 0.448 | 0.199 | 0.423 | 0.260 | 0.494 | 0.246 | 0.493 | 7.94×10−4 | 1.35 (1.13–1.61) | ||||
Combined | 0.361 | 0.450 | 0.189 | 0.414 | 0.235 | 0.526 | 0.239 | 0.498 | 2.58×10−10 | 1.43 (1.28–1.60) |
*Used in risk score calculation.
Genome Build 36.3.
Risk alleles were in bold.
P-values, ORs and CIs were calculated based on the additive effect model with age adjustment.